{"entity":{"id":"acr-2316","kind":"drug","name":"ACR-2316","aka":[],"tldr":"ACR-2316 is an experimental small molecule from Acrivon Therapeutics, in phase 1 trials for lung cancer, endometrial cancer and cervical cancer and other cancers.","summary":"ACR-2316 is a small molecule (oral) from Acrivon Therapeutics. A selective dual inhibitor of WEE1 and PKMYT1 that Acrivon designed with its AP3 phosphoproteomics platform. Its furthest stage is phase 1, for lung cancer, endometrial cancer, cervical cancer and oesophago-gastric junction cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 study moved into randomised dose expansion (Q2 2026 results release, 12 August 2026). Registry phase PHASE1/PHASE2, RECRUITING. Stage given as phase-1 because the study is phase 1/2 and is in dose expansion. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Acrivon Therapeutics: acrivon.com","url":"https://acrivon.com/pipeline/"},{"label":"Acrivon Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-ex99_1.htm"},{"label":"Acrivon Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06667141"},{"label":"ClinicalTrials.gov: trials of ACR-2316","url":"https://clinicaltrials.gov/search?intr=ACR-2316"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["wee1"],"drugs":[],"companies":["acrivon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06667141"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ACR-2316","modality":"Small molecule (oral)","mechanism":"A selective dual inhibitor of WEE1 and PKMYT1 that Acrivon designed with its AP3 phosphoproteomics platform.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/acr-2316/","neighbours":{"target":[{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/"}],"company":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/"}],"trial":[{"id":"nct06667141","kind":"trial","name":"Study of ACR-2316 in Specific Advanced Solid Tumors","route":"/trials/nct06667141/"}]}}